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Abstract: Importance: Multiple immunostimulatory agonist antibodies have been clinically tested in
solid tumors to evaluate the role of targeting glucocorticoid-induced tumor necrosis factor (TNF) receptor-
related protein in anticancer treatments. Objective: To evaluate the safety and activity of the fully human
glucocorticoid-induced TNF receptor-related protein agonist IgG1 monoclonal antibody BMS-986156
with or without nivolumab in patients with advanced solid tumors. Design, Setting, and Participants:
This global, open-label, phase 1/2a study of BMS-986156 with or without nivolumab enrolled 292 patients
18 years or older with advanced solid tumors and an Eastern Cooperative Oncology Group performance
status of 1 or less. Prior checkpoint inhibitor therapy was allowed. Monotherapy and combination dose-
escalation cohorts ran concurrently to guide expansion doses beginning October 16, 2015; the study is
ongoing. Interventions: The protein agonist BMS-986156 was administered intravenously at a dose of
10, 30, 100, 240, or 800 mg every 2 weeks as monotherapy, and in the combination group 30, 100, 240,
or 800 mg plus 240 mg of nivolumab every 2 weeks; same-dose cohorts were pooled for analysis. One
cohort also received 480 mg of BMS-986156 plus 480 mg of nivolumab every 4 weeks. Main Outcomes and
Measures: The primary end points were safety, tolerability, and dose-limiting toxic effects. Additional
end points included antitumor activity per Response Evaluation Criteria in Solid Tumors, version 1.1,
and exploratory biomarker analyses. Results: With a follow-up range of 1.4 to 101.7 weeks (follow-
up ongoing), 34 patients (16 women and 18 men; median age, 56.6 years [range, 28-75 years]) received
monotherapy (4 patients completed initial treatment), and 258 patients (140 women and 118 men; median
age, 60 years [range, 21-87 years]) received combination therapy (65 patients completed initial treatment).
No grade 3 to 5 treatment-related adverse events occurred with BMS-986156 monotherapy; grade 3 to 4
treatment-related adverse events occurred in 24 patients (9.3%) receiving BMS-986156 plus nivolumab,
with no grade 5 treatment-related adverse events. One dose-limiting toxic effect (grade 4 elevated creatine
phosphokinase levels) occurred in a patient receiving 800 mg of BMS-986156 plus 240 mg of nivolumab
every 2 weeks; BMS-986156 with or without nivolumab exhibited linear pharmacokinetics with dose-
related increase after a single dose. Peripheral T-cell and natural killer-cell proliferation increased after
administration of BMS-986156 with or without nivolumab. No consistent and significant modulation
of intratumoral CD8+ T cells and FoxP3+ regulatory T cells was observed. No responses were seen
with BMS-986156 alone; objective response rates ranged from 0% to 11.1% (1 of 9) across combination
therapy cohorts, with a few responses observed in patients previously treated with anti-programmed death
receptor (ligand) 1 therapy. Conclusions and Relevance: Based on this cohort, BMS-986156 appears to
have had a manageable safety profile, and BMS-986156 plus nivolumab demonstrated safety and efficacy
comparable to historical data reported for nivolumab monotherapy. Trial Registration: ClinicalTrials.gov
identifier: NCT02598960.
DOI: https://doi.org/10.1001/jamaoncol.2019.3848
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IMPORTANCE Multiple immunostimulatory agonist antibodies have been clinically tested in
solid tumors to evaluate the role of targeting glucocorticoid-induced tumor necrosis factor
(TNF) receptor–related protein in anticancer treatments.
OBJECTIVE To evaluate the safety and activity of the fully human glucocorticoid-induced TNF
receptor–related protein agonist IgG1 monoclonal antibody BMS-986156 with or without
nivolumab in patients with advanced solid tumors.
DESIGN, SETTING, AND PARTICIPANTS This global, open-label, phase 1/2a study of BMS-986156
with or without nivolumab enrolled 292 patients 18 years or older with advanced solid tumors
and an Eastern Cooperative Oncology Group performance status of 1 or less. Prior checkpoint
inhibitor therapy was allowed. Monotherapy and combination dose-escalation cohorts ran
concurrently to guide expansion doses beginning October 16, 2015; the study is ongoing.
INTERVENTIONS The protein agonist BMS-986156 was administered intravenously at a dose
of 10, 30, 100, 240, or 800mg every 2 weeks as monotherapy, and in the combination group
30, 100, 240, or 800mg plus 240mg of nivolumab every 2 weeks; same-dose cohorts were
pooled for analysis. One cohort also received 480mg of BMS-986156 plus 480mg of
nivolumab every 4 weeks.
MAIN OUTCOMES ANDMEASURES The primary end points were safety, tolerability, and
dose-limiting toxic effects. Additional end points included antitumor activity per Response
Evaluation Criteria in Solid Tumors, version 1.1, and exploratory biomarker analyses.
RESULTSWith a follow-up range of 1.4 to 101.7weeks (follow-up ongoing), 34 patients (16women
and 18men;median age, 56.6years [range, 28-75 years]) receivedmonotherapy (4patients
completedinitialtreatment),and258patients(140womenand118men;medianage,60years[range,
21-87 years]) received combination therapy (65patients completed initial treatment).Nograde3
to 5 treatment-related adverse events occurred with BMS-986156 monotherapy; grade 3 to 4
treatment-related adverse events occurred in 24 patients (9.3%) receiving BMS-986156 plus
nivolumab,withnograde5treatment-relatedadverseevents.Onedose-limitingtoxiceffect (grade
4elevated creatinephosphokinase levels) occurred in apatient receiving800mgofBMS-986156
plus240mgofnivolumabevery2weeks;BMS-986156withorwithoutnivolumabexhibited linear
pharmacokineticswithdose-related increase after a single dose. Peripheral T-cell andnatural
killer–cell proliferation increasedafter administrationofBMS-986156withorwithout nivolumab.
Noconsistentandsignificantmodulationof intratumoralCD8+TcellsandFoxP3+ regulatoryTcells
was observed.No responseswere seenwith BMS-986156 alone; objective response rates ranged
from0%to 11.1% (1 of9) across combination therapy cohorts,with a few responsesobserved in
patients previously treatedwith anti–programmeddeath receptor (ligand) 1 therapy.
CONCLUSIONS AND RELEVANCE Based on this cohort, BMS-986156 appears to have had a
manageable safety profile, and BMS-986156 plus nivolumab demonstrated safety and
efficacy comparable to historical data reported for nivolumabmonotherapy.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02598960
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I
mmunotherapy treatment options are broad and include
multiple approaches. One of the most successful strate-
gies thus far has been the blockade of T-cell inhibitory
checkpoints, such as cytotoxic T-lymphocyte–associated
antigen 4 and programmed death receptor 1 (PD-1), and
programmed death ligand 1 (PD-L1), to enhance the antitu-
mor immune response.1 Immune checkpoint inhibitors lead
to highly durable responses and significantly prolonged
overall survival in many advanced tumor types.2-4 Dual
checkpoint blockade, combining nivolumab with ipilim-
umab, has shown even more promising results in various
tumor types.5-10 Although checkpoint inhibitors have pro-
vided advancements in anticancer treatment, a significant
majority of patients, such as those with tumor types that are
mismatch repair proficient or noninflamed, remain unre-
sponsive to checkpoint inhibition.11-14 In addition, some
patients with initial response to checkpoint inhibition even-
tually experience disease progression and face limited sub-
sequent therapeutic options. Thus, new strategies for modu-
lating the critical balance of T-cell activation and antigen
tolerance that make an antitumor immune response possible
are being investigated.15-18
A variety of T-cell costimulatory receptors exist
whose activity and engagement may potentiate the T-cell
response induced by checkpoint inhibitors. Promising thera-
peutic targets include the tumor necrosis factor receptor
(TNFR) superfamily, such as the glucocorticoid-induced
TNFR-related protein (GITR), TNFR superfamily member 4
(CD134/OX40), and TNFR superfamily member 9 (CD137/4-
1BB). It was hypothesized that agonistic GITR antibodies may
successfully activate costimulatory pathways to synergize
with PD-1 inhibitors and PD-L1 inhibitors in the tumor
microenvironment.1 To date, several anti-GITR antibodies and
anti-GITR ligand antibodies have been used in clinical
trials.19-26
The protein agonist BMS-986156 is an IgG1 agonist
monoclonal antibody to GITR, a molecule that is constitu-
tively expressed by intratumoral regulatory T cells at high
levels and by effector T cells at low levels.27 In addition, GITR
becomes upregulated on effector T cells on their activation.
In preclinical studies, GITR engagement can deplete
GITR-expressing cells or can induce T-cell proliferation de-
pending on the system.27,28 BMS-986156 was engineered to
increase T-cell activation and deplete intratumoral regula-
tory T cells in combination with anti–PD-1 therapy. Preclini-
cal experiments with in vivo syngeneic mouse models
show enhanced antitumor activity when a GITR agonist
antibody is added to anti–PD-1 therapy.29Thus, itwashypoth-
esized that this combination may result in improved and
prolonged antitumor responses in patients with advanced
cancer.
In the present study, results are reported from a phase
1/2a dose-escalation and dose-expansion study investi-
gating the safety, tolerability, pharmacokinetics, pharmaco-
dynamics, and preliminary clinical activity profiles of
BMS-986156 as monotherapy treatment and in combination





Germany, Italy, the Netherlands, Spain, Switzerland, and the
United States participated in this study,which beganOctober
16, 2015, and is ongoing. Eligible patients were aged 18 years
or older with confirmed, previously treated advanced solid
tumors per Response Evaluation Criteria in Solid Tumors
(RECIST), version 1.131 andmust have received and then pro-
gressed on or been intolerant to 1 ormore standard treatment
regimens in the advanced or metastatic setting, if such a
therapyexisted.Other keyeligibility criteria includedanEast-
ernCooperativeOncologyGroupperformancestatusof 1or less.
Prior anti–PD-1 therapyoranti–PD-L1 therapywasallowed.The
study was conducted in compliance with the trial protocol
(Supplement 1). The protocol, any amendments, and the pa-
tient informed consent formwere reviewed and approved by
an institutional review board or independent ethics commit-
tee (Australia: Linear Clinical Research Ltd, Liverpool Cancer
TherapyCenter, PrincessAlexandraHospital,WestmeadHos-
pital; Belgium: Universitair Ziekenhuis Gent; Canada: Cross
Cancer Institute,PrincessMargaretCancerCentre;France:Cen-
tre Claudius Regaud, Institut Curie, Institut Gustave Roussy;
Germany: Klinikum Der Albrecht-Ludwigs-Universitat, Med.
Klinik Und Poliklinik D. Uni Wuerzburg, Universitaetsklini-
kumBonn; Italy: Istituto di Ricovero e Cura a Carattere Scien-
tifico Istituto Nazionale dei Tumori Milano, Istituto Europeo
DiOncologia;Netherlands:NKIAVL;Spain:FundacionJimenez
Diaz, Hosp Univer 12 De Octubre; Switzerland: Cantonal Hos-
pitalStGallen,UniversityHospitalZurich;UnitedStates:Emory
University,ProvidencePortlandMedicalCenter,TheOhioState
University, TheWest Clinic P.C., Thomas JeffersonUniversity
Hospital,UniversityofCaliforniaSanDiegoMooresCancerCen-
ter, University of Alabama at Birmingham) prior to initiation
of the study. Patients provided written informed consent.
Key Points
Question Is the glucocorticoid-induced tumor necrosis factor
receptor–related protein agonist BMS-986156 treatment with or
without nivolumab tolerable and clinically active in patients with
advanced solid tumors?
Findings In this open-label, phase 1/2a study of 292 treated
patients with advanced solid tumors (69 completed initial
treatment), BMS-986156 therapy had a tolerable safety profile;
combination therapy had a similar safety profile to that of
nivolumab. No responses were seen with monotherapy; however,
in combination therapy, response rates were comparable to those
historically observed with nivolumab (<15% across tumor types).
Meaning This study represents the largest data set on
glucocorticoid-induced tumor necrosis factor receptor–related
protein agonismwith or without nivolumab to our knowledge;
a clear signal has not emerged demonstrating that
glucocorticoid-induced tumor necrosis factor receptor–related
protein agonismmay be an effective therapeutic strategy in a
broad patient population.
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Study Design and Treatment
This phase 1/2a, open-label study investigatedBMS-986156as
monotherapy and in combinationwith nivolumab (study de-
sign, doses, and Consolidated Standards of Reporting Trials
[CONSORT]diagramshowninFigure 1; trialprotocol inSupple-
ment 1; and eFigure 1 in Supplement 2).
Study Outcomes
Theprimaryobjectiveof this studywas todetermine thesafety,
tolerability, dose-limiting toxic effects, and maximum toler-
ated dose of BMS-986156 either asmonotherapy or in combi-
nation with nivolumab in patients with advanced solid tu-
mors. Key secondary objectives included determining the
antitumoractivityandcharacterizing thepharmacokineticpro-
file and immunogenicity of BMS-986156 asmonotherapy and
in combination with nivolumab. Exploratory end points in-
cludednivolumabpharmacokinetics, overall survival, and the
pharmacodynamics of BMS-986156 plus nivolumab via pe-
ripheral blood and intratumoral biomarker analysis.
Safety
Adverse events were assessed using the National Cancer In-
stituteCommonTerminologyCriteria forAdverseEvents, ver-
sion 4.03.32 Adverse events were evaluated throughout the
studywhileparticipantswerereceiving treatmentanduntil 100
days after study completion.
Tumor Response
Assessment of tumor response was observed through com-
puted tomography and/ormagnetic resonance imaging at the
start of the study and every 8weeks until disease progression
or treatment termination via RECIST, version 1.1.
Statistical Analysis
Detailed information on exclusion criteria, study treatment,
andstatistical,pharmacokinetic, andpharmacodynamicanaly-
ses are described in the eAppendix in Supplement 2.
Results
Patient Characteristics
Detailed patient demographics are presented in eTable 1 in
Supplement 2. Baseline characteristics were similar between
themonotherapyandcombination therapycohorts. Prior anti–
PD-1 or anti–PD-L1 therapy was received by 11 of 34 patients
(32.4%) in the monotherapy cohort and 51 of 258 patients
(19.8%) in the combination cohort.
As of March 27, 2018, 34 patients received 10 to 800 mg
of BMS-986156monotherapy every 2weeks and 258 patients
received 30 to 800 mg of BMS-986156 plus 240 mg of
nivolumab every 2weeks or 480mg of BMS-986156 plus 480
mg of nivolumab every 4 weeks. Duration of therapy ranged
from 2.0 to 61.0 weeks, with follow-up time ranging from 1.4
to 101.7 weeks. Median treatment exposure (in weeks) is
presented in eTables 2A and 2B in Supplement 2. All patients
but 1 (n = 33)were able to receive 90%ormore of the planned
cumulative treatment dose of BMS-986156 in the dose-
escalationphase (4patients completed initial treatment), and
more than 80% of patients in each dose cohort of the combi-
nationphase (n = 227)were able to receive90%ormoreof the
planned cumulative treatment dose of both drugs (65 pa-
tients completed initial treatment).
Safety
Overall, the safety profile of BMS-986156 was tolerable. Any
treatment-related adverse events (TRAEs) by dose in the
BMS-986156 monotherapy cohort and in 5% or more of pa-
tients in the BMS-986156 plus nivolumab combination co-
horts, as well as any grade 3 or 4 TRAEs in either cohort, are
shown in eTables 3A and 3B in Supplement 2. Grades 3 and 4
TRAEsoccurredin24patients(9.3%)receivingBMS-986156plus
nivolumab.Nograde 5TRAEswere observedwith either treat-
ment. In addition, no TRAEs led to treatment discontinuation
in the BMS-986156 monotherapy cohort. Three TRAEs led to
Figure 1. CONSORTDiagram
292 Patients received treatment
4 Patients completed initial treatment
30 Patients did not complete
initial treatment
29 Disease progression
1 Adverse event unrelated
to study drug
193 Patients did not complete
initial treatment
6 Still receiving treatment
163 Disease progression
9 Adverse events unrelated
to study drug
6 Requested to discontinue
4 Other
3 Withdrew consent
2 Drug-related toxic effects
34 Patients treated with
BMS-986156a
258 Patients treated with BMS-986156
plus nivolumaba
65 Patients completed initial treatment
a This was not a randomized trial and
themonotherapy and combination
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treatment discontinuation of BMS-986156 plus nivolumab
(grade 3 colitis, infusion-related reaction, and pancreatitis, all
in the cohort receiving 240mg of BMS-986156 plus 240mg of
nivolumab). Grade 1 to 2 pyrexiawas seen in 6 patients (17.6%)
treatedwithBMS-986156monotherapyand28patients (10.9%)
treated with combination therapy, usually within 24 hours of
infusion without associated sequelae. Any grade and grades 3
and4seriousTRAEsoccurring in theoverallmonotherapyand
combination cohorts are shown in eTable 4 in Supplement 2.
Grade 2 pneumonitis was the only serious TRAE seen in pa-
tients treatedwith BMS-986156monotherapy.With combina-
tion therapy,most seriousTRAEswereobserved in the202pa-
tients who received 240 mg of BMS-986156 plus 240 mg of
nivolumabevery2weeks.Onedose-limiting toxiceffect (grade
4 elevated creatine phosphokinase level) occurred in a patient
receiving800mgofBMS-986156plus240mgofnivolumabev-




986156 plus nivolumab combination after the first dose is
shown in eFigure 2 in Supplement 2. Overall, the pharmaco-
kineticswas linear andexhibitedadose-related increase inex-
posure thatwas not affected in combinationwith nivolumab.
Immunogenicity with BMS-986156 monotherapy was
low; only 1 of 31 patients (at the dose of 10 mg every 2 weeks)
was antidrug antibody (ADA) positive, and no patients had
persistent ADA positivity (eTable 6A in Supplement 2). In the
combination cohort, the frequency of anti-GITR antibodies
at all tested doses of BMS-986156 remained low, with 223
of 229 patients (97.4%) remaining ADA negative, and no
persistently ADA-positive patients. Immunogenicity with
nivolumab was relatively higher, with 35 of 223 ADA-positive
patients (15.7%), and 1 of 223 patients (0.4%) persistently
positive, which is consistent with nivolumab monotherapy
(eTable 6B in Supplement 2).
Pharmacodynamics
In analyzed patients, there was a trend toward an increase in
CD8+ T-cell and natural killer–cell proliferation after admin-
istration of anti-GITR monotherapy tested up to a dose of
240mg every 2 weeks, although patient numbers were small
(eFigure 3 in Supplement 2). Enhanced CD8+ T-cell and natu-
ral killer–cell proliferation was observed in the combination
cohort.
In the subsetofpatientswithdataavailable atbaselineand
all analyzed timepoints, results of flowcytometry revealedno
clear depletion of regulatory T cells in the peripheral blood in
response toBMS-986156plusnivolumab (eFigure4 inSupple-
ment2). In addition,CD8+Tcells andFoxP3+ regulatoryTcells
as assessed by immunohistochemistry revealed interpatient
variability frombefore treatment to the treatmentperiodwith
BMS-986156 plus nivolumab (Figure 2).














































FoxP3+ regulatory T cellsB
Screening C1 D15
Tumor-infiltrating CD8+ T cells (P = .72) (A) and FoxP3+ regulatory T cells
(P = .44) (B) by immunohistochemistry biopsies before treatment and while
receiving treatment for 53matched pairs of patients receiving BMS-986156
plus nivolumab combination therapy (all patients included in this analysis
received 240mg of nivolumab every 2 weeks). TheWilcoxon signed rank test
was performed for all the comparisons. The horizontal line in each box plot
denotes themedian level. C1 D15 indicates cycle 1, day 15.
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Preliminary Clinical Activity
Response results for theBMS-986156monotherapycohort and
theBMS-986156plusnivolumabcombination cohort are sum-
marized inTable 1 andTable 2, and response results by tumor
type for the combination treatment cohort are summarized in
eTable 7 in Supplement 2. No complete or partial responses
were observed with BMS-986156 alone. Objective response
rates ranged from 0% to 11.1% (1 of 9) across combination
therapycohorts; anobjective response rateof9.0%(18of 200)
wasobserved in thepatient cohort evaluable for responsewho
received 240mg of BMS-986156 plus 240mg of nivolumab.
Discussion
Here, results are presented from a phase 1/2a dose-escalation
and dose-expansion study of the GITR agonistic antibody
BMS-986156 with or without nivolumab in 292 patients with
advanced solid tumors. Overall, the safety profile of BMS-
986156 monotherapy appeared to be manageable, with no
unanticipated safety signals, no dose-limiting toxic effects,
and no treatment discontinuations owing to TRAEs. The
findings suggest that the safety profile of BMS-986156
plus nivolumab at all doses was manageable and tolerable
and was similar to that of nivolumab alone.2,33,34 The rate of
infusion-related reactions with combination therapy was the
only TRAE that potentially appeared more frequently than
observed with nivolumab alone.2,33,34
Limitations
Some limitations of this trial include the absence of com-
parator groups and the enrollment of an unselected popula-
tion. For example, although combination therapy with
BMS-986156 plus nivolumab yielded pharmacodynamic
changes and clinical response rates similar to those histori-
cally observed with nivolumab monotherapy in patients
with advanced solid tumors (range, 13%-20%),2,33-35 this
trial was not designed to be a head-to-head comparison of
nivolumab monotherapy vs nivolumab plus BMS-986156.
Thus, without an appropriate comparator group (eg,
nivolumab monotherapy), dissecting the effects of BMS-
986156 and nivolumab is difficult, and the contribution of
the GITR agonist to the combinatorial clinical activity
remains unclear. In addition, no tumor type appeared to
respond more favorably to combination therapy vs others.
Most observed responses occurred in patients without prior
anti–PD-1 or anti–PD-L1 therapy, although a few responses
were observed in patients with prior anti–PD-1 or anti–PD-L1
therapy. Overall, however, the data appear to indicate the
absence of substantial clinical activity of BMS-986156 in an
unselected, broad population of patients with advanced
solid tumors.




























CR 0 0 2 (1.0) 0 0
PR 0 1 (11.1)a 16 (8.0)b,c 1 (9.1) 1 (3.4)
SD 1 (33.3) 2 (22.2) 65 (32.5) 5 (45.5) 11 (37.9)
PD 2 (66.7) 4 (44.4) 95 (47.5) 4 (36.4) 12 (41.4)



























Abbreviations: BOR, best overall
response; CR, complete response;
DCR, disease control rate; NE, not
evaluable; ORR, objective response
rate; PD, progressive disease;
PR, partial response;
SD, stable disease.
a This patient had prior treatment
with pembrolizumab, with a BOR of
PD, ending 111 weeks before
initiation of study treatment.
bOne of these patients had prior
treatment with nivolumab, with a
BOR of PD, ending 4 weeks before
initiation of study treatment.
c One of these patients had prior
treatment with pembrolizumab,
with a BOR of PR, ending 83 weeks
before initiation of study treatment.


















CR 0 0 0 0 0
PR 0 0 0 0 0
SD 2 (50.0) 1 (16.7) 2 (50.0) 2 (22.2) 4 (36.4)
PD 1 (25.0) 3 (50.0) 2 (50.0) 6 (66.7) 6 (54.5)
NE 1 (25.0) 2 (33.3) 0 1 (11.1) 1 (9.1)
Confirmed ORR,
% (95% CI)
0 (0.0-60.2) 0 (0.0-45.9) 0 (0.0-60.2) 0 (0.0-33.6) 0 (0.0-28.5)
Confirmed DCR,











Abbreviations: BOR, best overall
response; CR, complete response;
DCR, disease control rate; NE, not
evaluable; ORR, objective response
rate; PD, progressive disease;
PR, partial response;
SD, stable disease.
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Similar observationsof a tolerable safetyprofile and some
immunomodulatory action, but limited clinical activity, have
beenmadewithotherGITRagonist antibodies in clinical trials;
across 4 other studies, more than 100 patients have been
treatedwithGITRagonistmonotherapy,demonstratingaman-
ageable safety profile and limited clinical activity (the best
overall response observedwas stable disease).19,21,22,36Based
on current available data, to date, no synergistic activity has
been observed between GITR agonists and pembrolizumab
when administered as a combination treatment, except po-
tentially in checkpoint inhibitor–naive patients with mela-
noma, based on a small cohort of 13 patients.21,37
Although checkpoint inhibitors have made strides in
revolutionizing cancer therapy, to our knowledge, there has
not been a clear path identified to date for costimulatory
therapy combinations. Other members of the TNFR super-
family and classes of costimulatory molecules that are
mechanistically different from TNFR are also under investi-
gation, including inducible costimulator, a member of the
CD28 family, which promotes T-cell proliferation and cyto-
kine production after T-cell activation.15 The potential role
of combination checkpoint inhibition plus agonistic induc-
tion of costimulatory T-cell pathways in certain patient sub-
sets with immunotherapy-resistant or refractory tumors
remains to be determined.
Conclusions
To our knowledge, this represents the largest clinical data
set investigating GITR agonist therapy (BMS-986156) with
or without nivolumab. We believe that BMS-986156 has a
manageable safety profile, and its combination with
nivolumab seems to show a similar safety signal to that of
nivolumab monotherapy. Clinical activity of anti-GITR
therapy plus anti–PD-1 therapy was similar to historically
observed activity with anti–PD-1 therapy alone. Thus, no
evidence of monotherapeutic clinical activity for GITR ago-
nism was observed in this broad population. In addition, no
clear signal has emerged to date demonstrating that GITR
agonism may be an effective therapeutic strategy in a broad
patient population.
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